Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026
- Participants achieving HBsAg loss with pegylated interferon alfa (PEG-IFNα) ± elebsiran or BRII-179 demonstrated favorable off-treatment clinical outcomes, with most HBsAg rebounds <10 IU/mL and HBV DNA rebound infrequent and not associated...
Brii Biosciences Provides Corporate Updates and Reports Full Year 2025 Financial Results
Advancing HBV Functional Cure Toward Key Phase 2b Data Readouts Increasing Discovery Efforts to Drive Long-term Value Creation Strong Cash Position Supporting Strategic Priorities Upcoming Conference Calls: English Session: March 20 at 8:30 p.m. HKT...
Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results
Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure Data from Multiple Ongoing Late-Stage Studies Reinforce Brii Bio's HBV Functional Cure...